D. W. Kim

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

Sabrina Angelini, Simona Soverini, Gloria Ravegnini et al. · Haematologica · 2012 · 113 citations · Full text

Veterinary Medicine, Genetics, Pharmacology +14

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

John F. Seymour, D. W. Kim, E Rubin et al. · Blood Cancer Journal · 2014 · 64 citations · Full text

Medicine, Hematology, Oncology +17

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

Deborah L. White, Jerald P. Radich, Simona Soverini et al. · Haematologica · 2011 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034

Neha Shah, D. W. Kim, Hagop M. Kantarjian et al. · Journal of Clinical Oncology · 2007 · 33 citations

Medicine, Pharmacology, Pharmacotherapy +13